An announcement from Argent Biopharma ( (AU:RGT) ) is now available.
Argent BioPharma has achieved a significant milestone with the approval of its cannabinoid-based therapy, CannEpil™, for prescription in Germany. This approval not only marks a critical expansion into the European market but also enhances the company’s position in neuroimmune modulation and CNS-focused therapeutics. With approximately 816,000 people affected by epilepsy in Germany, many of whom suffer from drug-resistant forms, CannEpil™ offers a promising alternative to traditional treatments. The approval facilitates broader adoption of Argent’s therapies in the EU, ensuring life-changing treatment access for patients and aligning with the company’s mission to innovate in medical solutions.
More about Argent Biopharma
Argent BioPharma Limited is a clinical-stage biopharmaceutical company specializing in neuroimmunology and advanced nanomedicine. The company focuses on leveraging the Neuro-Immune Modulatory (NIM) System to develop a robust pipeline of therapies targeting central nervous system disorders and immune-related conditions. Argent BioPharma is committed to science-driven innovation in cannabinoid-based therapeutics and neuroimmune modulation.
YTD Price Performance: -52.50%
Average Trading Volume: 135,660
Technical Sentiment Signal: Buy
Current Market Cap: $6.34M
For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.